Supreme Court rejects appeals from drug manufacturers over Medicare price negotiations with government
The negotiation program was created as part of the 2022 Inflation Reduction Act, which capped years of debate over whether the federal government should be allowed to haggle directly with manufacturers over the prices of drugs in Medicare.
Original Source
Read the full article at Pbs →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.